Research programme: renal failure therapy - Theratechnologies

Drug Profile

Research programme: renal failure therapy - Theratechnologies

Alternative Names: THG 21329; THG213.29

Latest Information Update: 13 Nov 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Theratechnologies
  • Class Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Renal failure

Most Recent Events

  • 30 Oct 2012 Suspended - Preclinical for Renal failure in Canada (unspecified route)
  • 21 Oct 2010 Preclinical development is ongoing in Canada
  • 20 Mar 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top